Attovia Therapeutics, Inc. has filed an amendment to a previous Form 4 regarding stock options granted to its Chief Financial Officer, Steven Chan. This amendment, filed on October 8, 2026, is significant as it clarifies the vesting schedule of the stock options and updates the reporting details for the executive.
Attovia Therapeutics operates within the biological products sector, specifically classified under SIC 2836, which includes companies involved in the development of biological products excluding diagnostic substances. The company trades on the Nasdaq under the ticker symbol ATTO.
The recent filing indicates that Chan was granted stock options to purchase 140,000 shares of common stock at an exercise price of $17 per share. The transaction date for these options was August 4, 2026. According to the filing, 25% of the options will vest on August 4, 2027, with the remaining options vesting in equal monthly installments over the following three years, contingent on continued service to the company.
This amendment serves to replace a previous Form 4 filed on August 6, 2026, which reported Chan's beneficial ownership using the Issuer's CIK number. The new filing has been made under Chan's own CIK, ensuring accuracy in reporting and transparency for investors.
The impact of this filing may resonate with various stakeholders, including investors and analysts monitoring executive compensation and governance practices in the biological products sector. Such transparency is essential for maintaining investor confidence, especially in a competitive landscape where companies are vying for market share.
The filing does not specify what actions will follow this amendment. It remains to be seen if further updates or changes will be made regarding executive compensation or other governance matters within Attovia Therapeutics.